home All News open_in_new Full Article

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement Findings to form the basis […]


today 9 h. ago attach_file Other

attach_file Politics
attach_file Other
attach_file Culture
attach_file Politics
attach_file Other
attach_file Culture
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Events
attach_file Other
attach_file Events
attach_file Sport
attach_file Other
attach_file Politics
attach_file Society
attach_file Other
attach_file Other
attach_file Other


ID: 1341060451
Add Watch Country

arrow_drop_down